Tuberculosis into the 2010s

Is the Glass Half Full?

Research output: Contribution to journalArticleResearchpeer-review

Abstract

During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. However, during this period, we have also witnessed the creation of-and major commitments from-agencies dedicated to TB control, research, and funding, and tangible positive achievements have occurred; these include improvements in both new and existing TB diagnostics, a developmental pipeline of new candidate TB drugs, better treatment outcomes for multidrug-resistant TB and XDR-TB, heightened recognition of the importance of nosocomial transmission, and improved strategies to reduce mortality associated with concurrent human immunodeficiency virus infection and TB. We suggest updates to the 2006 International Standards of Tuberculosis Care to embrace these developments. The incorporation of these recent advances into optimized directly observed treatment, short course (DOTS), programs, in conjunction with more widespread deployment and enhanced political will, all provide grounds for improved control. � 2009 by the Infectious Diseases Society of America. All rights reserved.
Original languageEnglish
Pages (from-to)574-583
Number of pages10
JournalClinical Infectious Diseases
Volume49
Issue number4
Publication statusPublished - 2009

Fingerprint

Glass
Tuberculosis
Virus Diseases
Extensively Drug-Resistant Tuberculosis
HIV
Multidrug-Resistant Tuberculosis
Standard of Care
Emergencies
Mortality
Research
Pharmaceutical Preparations

Cite this

@article{b3318427800b4c7590f9173c5adbdb4a,
title = "Tuberculosis into the 2010s: Is the Glass Half Full?",
abstract = "During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. However, during this period, we have also witnessed the creation of-and major commitments from-agencies dedicated to TB control, research, and funding, and tangible positive achievements have occurred; these include improvements in both new and existing TB diagnostics, a developmental pipeline of new candidate TB drugs, better treatment outcomes for multidrug-resistant TB and XDR-TB, heightened recognition of the importance of nosocomial transmission, and improved strategies to reduce mortality associated with concurrent human immunodeficiency virus infection and TB. We suggest updates to the 2006 International Standards of Tuberculosis Care to embrace these developments. The incorporation of these recent advances into optimized directly observed treatment, short course (DOTS), programs, in conjunction with more widespread deployment and enhanced political will, all provide grounds for improved control. � 2009 by the Infectious Diseases Society of America. All rights reserved.",
keywords = "1 (6 bromo 2 methoxy 3 quinolinyl) 4 dimethylamino 2 (1 naphthyl) 1 phenyl 2 butanol, 2,3 dihydro 2 methyl 6 nitro 2 [4 [4 (4 trifluoromethoxyphenoxy) 1 piperidinyl]phenoxymethyl]imidazo[2,1 b]oxazole, 6,7 dihydro 2 nitro 6 (4 trifluoromethoxybenzyloxy) 5h imidazo[2,1 b][1,3]oxazine, amikacin, aminosalicylic acid, amoxicillin plus clavulanic acid, BCG vaccine, benzothiazine derivative, btz 043, capreomycin, clofazimine, cycloserine, ethambutol, ethionamide, gatifloxacin, isoniazid, kanamycin, levofloxacin, linezolid, ll 3858, moxifloxacin, n (2 adamantyl) n' geranylethylenediamine, nitroimidazole derivative, ofloxacin, protionamide, pyrazinamide, quinoline derivative, rifabutin, rifampicin, sq 609, streptomycin, terizidone, thioacetazone, tuberculostatic agent, unclassified drug, unindexed drug, bacterial transmission, comorbidity, directly observed therapy, funding, hospital infection, human, Human immunodeficiency virus infection, medical research, mortality, multidrug resistance, politics, priority journal, review, short course therapy, superinfection, treatment outcome, tuberculosis, tuberculosis control, world health organization, Communicable Disease Control, HIV Infections, Humans, Tuberculosis",
author = "A RALPH and Nicholas Anstey and P KELLY",
year = "2009",
language = "English",
volume = "49",
pages = "574--583",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

Tuberculosis into the 2010s : Is the Glass Half Full? / RALPH, A; Anstey, Nicholas; KELLY, P.

In: Clinical Infectious Diseases, Vol. 49, No. 4, 2009, p. 574-583.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Tuberculosis into the 2010s

T2 - Is the Glass Half Full?

AU - RALPH, A

AU - Anstey, Nicholas

AU - KELLY, P

PY - 2009

Y1 - 2009

N2 - During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. However, during this period, we have also witnessed the creation of-and major commitments from-agencies dedicated to TB control, research, and funding, and tangible positive achievements have occurred; these include improvements in both new and existing TB diagnostics, a developmental pipeline of new candidate TB drugs, better treatment outcomes for multidrug-resistant TB and XDR-TB, heightened recognition of the importance of nosocomial transmission, and improved strategies to reduce mortality associated with concurrent human immunodeficiency virus infection and TB. We suggest updates to the 2006 International Standards of Tuberculosis Care to embrace these developments. The incorporation of these recent advances into optimized directly observed treatment, short course (DOTS), programs, in conjunction with more widespread deployment and enhanced political will, all provide grounds for improved control. � 2009 by the Infectious Diseases Society of America. All rights reserved.

AB - During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant (XDR)-TB and its overlap with human immunodeficiency virus infection. However, during this period, we have also witnessed the creation of-and major commitments from-agencies dedicated to TB control, research, and funding, and tangible positive achievements have occurred; these include improvements in both new and existing TB diagnostics, a developmental pipeline of new candidate TB drugs, better treatment outcomes for multidrug-resistant TB and XDR-TB, heightened recognition of the importance of nosocomial transmission, and improved strategies to reduce mortality associated with concurrent human immunodeficiency virus infection and TB. We suggest updates to the 2006 International Standards of Tuberculosis Care to embrace these developments. The incorporation of these recent advances into optimized directly observed treatment, short course (DOTS), programs, in conjunction with more widespread deployment and enhanced political will, all provide grounds for improved control. � 2009 by the Infectious Diseases Society of America. All rights reserved.

KW - 1 (6 bromo 2 methoxy 3 quinolinyl) 4 dimethylamino 2 (1 naphthyl) 1 phenyl 2 butanol

KW - 2,3 dihydro 2 methyl 6 nitro 2 [4 [4 (4 trifluoromethoxyphenoxy) 1 piperidinyl]phenoxymethyl]imidazo[2,1 b]oxazole

KW - 6,7 dihydro 2 nitro 6 (4 trifluoromethoxybenzyloxy) 5h imidazo[2,1 b][1,3]oxazine

KW - amikacin

KW - aminosalicylic acid

KW - amoxicillin plus clavulanic acid

KW - BCG vaccine

KW - benzothiazine derivative

KW - btz 043

KW - capreomycin

KW - clofazimine

KW - cycloserine

KW - ethambutol

KW - ethionamide

KW - gatifloxacin

KW - isoniazid

KW - kanamycin

KW - levofloxacin

KW - linezolid

KW - ll 3858

KW - moxifloxacin

KW - n (2 adamantyl) n' geranylethylenediamine

KW - nitroimidazole derivative

KW - ofloxacin

KW - protionamide

KW - pyrazinamide

KW - quinoline derivative

KW - rifabutin

KW - rifampicin

KW - sq 609

KW - streptomycin

KW - terizidone

KW - thioacetazone

KW - tuberculostatic agent

KW - unclassified drug

KW - unindexed drug

KW - bacterial transmission

KW - comorbidity

KW - directly observed therapy

KW - funding

KW - hospital infection

KW - human

KW - Human immunodeficiency virus infection

KW - medical research

KW - mortality

KW - multidrug resistance

KW - politics

KW - priority journal

KW - review

KW - short course therapy

KW - superinfection

KW - treatment outcome

KW - tuberculosis

KW - tuberculosis control

KW - world health organization

KW - Communicable Disease Control

KW - HIV Infections

KW - Humans

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=67651089506&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 574

EP - 583

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -